Dr. John Cush RheumNow
3 years ago
Hepatotoxicity related to Anakinra has been reported in pediatric rheumatology patients. LFT elevations have been reported with IL-1 inhibition, even after excluding LFTs from the inflamm Dx, other drugs, MAS, etc. Here are 3 case reports. https://t.co/6ZxIcHbUEd https://t.co/Cx0kbn7JU2
Dr. John Cush RheumNow
3 years ago
FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/XiikNr3hWO https://t.co/Xd66zgvoDv
Dr. John Cush RheumNow
3 years ago
Safety Profile of a JAKi in Patients with RA With up to 6.5 Years of Exposure
Long-term JAKi safety data in patients with RA from 6 clinical studies is available to view in the RheumNow virtual poster hall. Sponsored by AbbVie US Medical Affairs. https://t.co/c4mYjdLKW7 https://t.co/lXh5klx0cq
Dr. John Cush RheumNow
3 years ago
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that #PMR patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
https://t.co/k5SAshxdsg https://t.co/tMtRHn2C6j
Dr. John Cush RheumNow
3 years ago
Registration is now open! Early bird pricing is available until 11/30/23. See you there!
https://t.co/zjXyldwlyl https://t.co/CpQ00745c1
Dr. John Cush RheumNow
3 years ago
#PMR: Is There Hidden GCA?
Dr. Anisha Dua, asks the question: in PMR should you worry about occult GCA?
https://t.co/Cd6u2GwJuo
@anisha_dua https://t.co/dWUH4zudPc
Dr. John Cush RheumNow
3 years ago
UK researchers develop a human vascularised synovium-on-a-chip: mechanically stimulated, 3D, microfluidic device w/ synovial cells and blood vessel cells to investigate syn inflammation & monocyte recruitment, mimics the forces applied w/ joint movement https://t.co/qlRHSE3o2b https://t.co/dsKvcsyysa
Dr. John Cush RheumNow
3 years ago
Turkish study 1,134 PsA pts found mean Dx delay=35 mos (median: 12). 39% Dx w/in 3 mos, & 67% w/in 24 mos. Dx delay decr. over time: 60 to 24 mos (<2010 to 2015–2019). Dx delay factors: less education (OR 2.6), arthritis>PSO (1.7), LBP 1st (1.6)https://t.co/q6aqtcaTxS https://t.co/uZSgoYuxJT
Dr. John Cush RheumNow
3 years ago
#PMR with Cancer
Dr. Sebastian Sattui (Pittsburgh, PA) Can PMR be a paraneoplastic presentation? QD Clinics are video vignettes with lessons from the clinic.
https://t.co/YhTkKpmzIl
@sattuiSEMD https://t.co/FTsz3QA5Cn
Dr. John Cush RheumNow
3 years ago
IL-6 Inhibitors in #PMR: Give early or late?
https://t.co/tMdriuFPYB https://t.co/WMhuogIMJC
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com.
Full Read review of #PMR in Lancet: - Start @ 12·5–25mg prednisone qd - Remission in most but, relapses in 40–60% - Onset sudden; AM stiffness predominates; Shoulders>Pelvic ~50% have distal MSK Sxs - US: look for B/L sub-acromial/deltoid bursitis https://t.co/GJDGjOD7oX
Dr. John Cush RheumNow
3 years ago
Draw Your Arthralgias
Featuring Dr. David Liew (Melbourne, Australia)
54 yr old with polyarthralgias, & slightly abnormal labs; could this be #PMR?
https://t.co/siP6Kv1Z1X https://t.co/cMy5ZTybUn
Dr. John Cush RheumNow
3 years ago
FDA Approves IV Secukinumab
On 10/6/23, Novartis announced the FDA approved an IV formulation of secukinumab (Cosentyx) for use in treating adults with PsA, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)
https://t.co/yt2GtawuDp https://t.co/FUMFnIXFkk
